SJ-600 Series (with SillaJen)
Oncology
Pre-clinicalActive
Key Facts
About ReiThera
ReiThera is a dual-focus Italian biotech, functioning both as a specialized CDMO for viral vectors and as a developer of its own therapeutic candidates. Its core expertise lies in viral vector engineering and scalable GMP manufacturing for adenoviruses, AAV, Lentivirus, MVA, and Herpes Simplex vectors. The company is advancing a clinical-stage HIV vaccine candidate in partnership with major research institutes and is actively involved in outbreak response efforts, such as for Marburg virus, while serving a global client base from its state-of-the-art facility in Rome.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |